New Bioprocessing Strategies: Development and Manufacturing of Recombinant Antibodies and Proteins (eBook, PDF)

Redaktion: Kiss, Bob; Pohlscheidt, Michael; Gottschalk, Uwe

• Format: PDF

Produktbeschreibung

Covers trends in modern biotechnology

All aspects of this interdisciplinary technology, where knowledge, methods and expertise are required from chemistry, biochemistry, microbiology, genetics, chemical engineering and computer science, are treated

More information as well as the electronic version available at springer.com

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Springer International Publishing
• Seitenzahl: 469
• Erscheinungstermin: 6. Dezember 2018
• Englisch
• ISBN-13: 9783319971100
• Artikelnr.: 54735290

Inhaltsangabe

Market and Capacity evolvement of the Biopharmaceutical Industry.- New Mammalian Expression Systems.- Innovation in seed train cultivation and production culture.- Manufacturing of Proteins and Antibodies / Risk mitigation for the contamination by adventitious agents.- Harvest operations.- Downstream Processing Technologies / Capturing and Final Purifaction.- Fully disposable manufacturing concepts for clinical and commercial manufacturing and Ballroom Concepts.- Augmented Reality - PAT and Artificial Intelligence for innovative process monitoring and controls.- Trends and innovations in formulations, fill and finish technologies and drug delivery.- Process Integration towards continuous manufacturing.- Future direction of Manufacturing of novel molecular format - a research perspective (bispecific antibodies, ADC, Ab fragments, fusion proteins, etc.- Cell therapy manufacturing for modern therapeutics.- Gene therapy.- Modern technologies and strategies for vaccine manufacturing.- Product and Technology Lifecycle Management in the Pharmaceutical Industry.- Integrated High Throughput Development.- A different perspective - How much innovation is really needed for production of mAb by mammalian cell technology?